← Back to Piramal Pharma Ltd. overview
Piramal Pharma Ltd. — 10-Year Financials
Annual P&L, balance sheet, and key ratios from public BSE/NSE filings.
| Period | Revenue | Net Profit | EPS (₹) | Total Assets | Shareholder Equity | ROE (%) | ROCE (%) | D/E | Net Margin (%) |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹9,061 cr | ₹91 cr | ₹0.68 | ₹15,678 cr | ₹8,125 cr | 1.12% | 6.41% | 0.6x | 1.01% |
| FY2024 | ₹8,106 cr | ₹18 cr | ₹0.14 | ₹15,312 cr | ₹7,911 cr | 0.23% | 4.96% | 0.6x | 0.22% |
| FY2023 | ₹7,032 cr | ₹-186 cr | ₹-1.54 | ₹14,523 cr | ₹6,774 cr | -2.75% | 1.75% | 0.83x | -2.65% |
| FY2022 | ₹6,472 cr | ₹376 cr | ₹3.09 | ₹12,797 cr | ₹6,697 cr | 5.61% | 6.22% | 0.62x | 5.81% |
Revenue: Total income from operations (₹ crore).
EPS: Earnings per share (₹), basic.
ROE: Net profit / average shareholder equity.
ROCE: EBIT / capital employed.
D/E: Total debt / shareholder equity.
Net Margin: Net profit as a % of revenue.
All figures sourced from public BSE/NSE filings. Ratios are pre-computed estimates and may differ from primary filings due to rounding.
Educational content — not investment adviceAll financial data is sourced from public filings and shown here for educational purposes only. EquitiesIndia.com is not a SEBI-registered Investment Adviser or Research Analyst. Nothing on this page constitutes a recommendation or solicitation to transact in any security. All data is at least 90 days old. Past performance is not indicative of future results.